CYTK Cytokinetics Incorporated

10.97
-0.37  -3%
Previous Close 11.34
Open 11.22
Price To Book -137.12
Market Cap 643,707,467
Shares 58,678,894
Volume 320,809
Short Ratio
Av. Daily Volume 408,577
Stock charts supplied by TradingView

NewsSee all news

  1. Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational

  2. Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate

  3. Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial

  4. Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals

    Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15th, 2019 SOUTH SAN FRANCISCO, Calif., Sept. 25,

  5. Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting

    Pharmacokinetic/Pharmacodynamic Relationship in Humans Similar to Preclinical Findings  Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 2019

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data presented at AAN, May 5, 2019, failed to meet primary endpoint.
Reldesemtiv (CK-2127107) - FORTITUDE-ALS
Amyotrophic lateral sclerosis (ALS)
Phase 1b interim analysis noted lack of efficacy.
CK-2127107
Limited mobility
Phase 3 interim analysis 1H 2020.
Omecamtiv mecarbil GALACTIC-HF
Acute heart failure
Phase 3 data released November 21, 2017 - primary endpoint not met.
Tirasemtiv - VITALITY
Amyotrophic lateral sclerosis (ALS)
Phase 2 data did not meet endpoints - October 5, 2018.
Reldesemtiv (CK-2127107)
Chronic obstructive pulmonary disease (COPD)
Second Phase 3 trial initiation announced February 21, 2019.
Omecamtiv mecarbil METEORIC-HF
Acute heart failure
Phase 2 trial to commence 4Q 2019.
CK-3773274
Obstructive hypertrophic cardiomyopathy
Phase 1 trial initiation announced February 20, 2019.
AMG 594
Healthy volunteers

Latest News

  1. Cytokinetics Announces Presentation of Additional Analyses From FORTITUDE-ALS at the 18th Annual NEALS Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced additional analyses of FORTITUDE-ALS (Functional Outcomes in a Randomized Trial of Investigational

  2. Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate

  3. Cytokinetics Announces Additional Results From FORTITUDE-ALS to be Presented at the 18th Annual NEALS Meeting

    SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that additional results from FORTITUDE-ALS (Functional Outcomes in a Randomized Trial

  4. Cytokinetics Announces Second Annual Communications Fellowship Program Call for Proposals

    Grants Support Community Engagement for Patient Advocacy Organizations Focused on Cardiovascular or Neuromuscular Diseases Deadline for Applications is November 15th, 2019 SOUTH SAN FRANCISCO, Calif., Sept. 25,

  5. Cytokinetics Announces Data From Phase 1 Study of CK-3773274 at the HFSA 23ʳᵈ Annual Scientific Meeting

    Pharmacokinetic/Pharmacodynamic Relationship in Humans Similar to Preclinical Findings  Data Support Progression to Phase 2 Clinical Trial in Patients with Obstructive Hypertrophic Cardiomyopathy to Begin in Q4 2019

  6. Cytokinetics Announces Presentations at the 23rd Annual HFSA Scientific Meeting

    SOUTH SAN FRANCISCO, Calif., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced two poster presentations at the 23rd Annual Heart Failure Society of America (HFSA) Scientific

  7. Cytokinetics to Present at September Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate

  8. Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA

    ELK GROVE VILLAGE, Ill. and SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Cure SMA and Cytokinetics (NASDAQ:CYTK) today announced the renewal of their partnership to increase education, awareness,